Results 141 to 150 of about 38,738 (212)

Additive Benefits of Control-IQ+ AID to GLP-1 Receptor Agonist Use in Adults With Type 2 Diabetes. [PDF]

Diabetes Care
Graham TE, Raghinaru D, Afreen S, Ahmann A, Haidar A, Raskin P, Tsoukas MA, Lum JW, Sasson-Katchalski R, Pinsker JE, Beck RW, 2IQP Study Group* .   +11 more
europepmc   +1 more source

<i>In silico</i> investigations of albumin-GLP-1 receptor agonist complexes for diabetes drug delivery applications. [PDF]

Comput Struct Biotechnol J
Murphy G, Cheung D, Fitzgerald M, Pandit A.   +3 more
europepmc   +1 more source

Prevalence and Factors Associated with GLP-1 Receptor Agonist Use for Weight Management Among Overweight and Obese Adults in the Eastern Province of Saudi Arabia. [PDF]

Healthcare (Basel)
Alhussain K, Alshakhs Z, Albaqshi L, Alshaqaqiq F, Alrabiah M, Tripathi R.   +5 more
europepmc   +1 more source

Neurobeachin (NBEA) is a novel gene associated with GLP-1 receptor agonist associated weight loss. [PDF]

Diabetes Obes Metab
Mariam-Smith A, Breeyear JH, Daniels NJ, Pantalone KM, Griebeler ML, Motsinger-Reif AA, Rotroff DM.   +6 more
europepmc   +1 more source

Factors Associated with GLP-1 Receptor Agonist Use in Patients with Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Retrospective Propensity-Score Matched Analysis. [PDF]

Diseases
Vournas G, Mourgos L, Doumas M, Liberopoulos EN, Kotsa K, Koufakis T.   +5 more
europepmc   +1 more source

Should GLP-1 receptor agonist therapy be used to treat obesity in Bardet-Biedl syndrome? [PDF]

J Clin Invest
Tomlinson JW.
europepmc   +1 more source

Impact of GLP-1 Receptor Agonist Therapy on Atrial Fibrillation Recurrence After Catheter Ablation in Obese Patients: A Real-World Data Analysis. [PDF]

Circ Arrhythm Electrophysiol
Venier S, Defaye P, Lochon L, Benali R, Bisson A, Carabelli A, Diouf Y, Jacon P, Fauchier L.   +8 more
europepmc   +1 more source

Efficacy and safety of bofanglutide, a GLP-1 receptor agonist, in Chinese adults with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial. [PDF]

Signal Transduct Target Ther
Ji L, Gao L, Tian J, Dong R, Zhang Z, Shu H, Zhao J, Zhao L, He A, Xie T, Li Y, Chen W.   +11 more
europepmc   +1 more source